Patents by Inventor Michael Lundkvist

Michael Lundkvist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Separation of Network Function and Its Realization
    Publication number: 20240179079
    Abstract: A network node modifies an association between the 3GPP defined Network Functions (NFs) and one or more cloud-native services thereby changing how those NFs are realized by the cloud-native services. To accomplish this, the node (200) “decouples” the NFs from the cloud-native services such that the NFs are unaware of the underlying cloud-native services that realize them and orchestrates the cloud-native services executing in the cloud that will realize those NFs. Additionally, the node automatically deploys, upgrades, scales, and heals the cloud-native services, as well as exposes the NFs and their interfaces, thereby facilitating the management of fault, configuration, accounting, performance, and security (FCAPS).
    Type: Application
    Filed: March 25, 2021
    Publication date: May 30, 2024
    Inventors: Cormac Mullally, Michael Lundkvist, Brian Sweeney, Dermot Melia
  • Chemical compounds
    Patent number: 10954211
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 23, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
  • Chemical Compounds
    Publication number: 20190330187
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Application
    Filed: May 10, 2019
    Publication date: October 31, 2019
    Inventors: Susanne Elisabeth BERGLUND, Stephen CONNOLLY, Martin HEMMERLING, Nafizal HOSSAIN, Anna KRISTOFFERSSON, Johan Rune Michael LUNDKVIST, Grigorios NIKITIDIS, Lena Elisabeth RIPA, Igor SHAMOVSKY
  • Chemical compounds
    Patent number: 10336725
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: July 2, 2019
    Assignee: AstraZeneca AB
    Inventors: Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
  • Chemical Compounds
    Publication number: 20180162838
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Application
    Filed: December 13, 2017
    Publication date: June 14, 2018
    Inventors: Susanne Elisabeth BERGLUND, Stephen CONNOLLY, Martin HEMMERLING, Nafizal HOSSAIN, Anna KRISTOFFERSSON, Johan Rune Michael LUNDKVIST, Grigorios NIKITIDIS, Lena Elisabeth RIPA, Igor SHAMOVSKY
  • Chemical compounds
    Patent number: 9873678
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: January 23, 2018
    Assignee: AstraZeneca AB
    Inventors: Susanne Elisabeth Berglund, Stephen Connolly, Martin Hemmerling, Nafizal Hossain, Anna Kristoffersson, Johan Rune Michael Lundkvist, Grigorios Nikitidis, Lena Elisabeth Ripa, Igor Shamovsky
  • Chemical Compounds
    Publication number: 20170107195
    Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
    Type: Application
    Filed: March 17, 2015
    Publication date: April 20, 2017
    Applicant: AstraZeneca AB
    Inventors: Susanne Elisabeth BERGLUND, Stephen CONNOLLY, Martin HEMMERLING, Nafizal HOSSAIN, Anna KRISTOFFERSSON, Johan Rune Michael LUNDKVIST, Grigorios NIKITIDIS, Lena Elisabeth RIPA, Igor SHAMOVSKY
  • Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
    Patent number: 8466284
    Abstract: The invention provides certain novel compounds as listed in the specification and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: June 18, 2013
    Assignee: Astra Zeneca AB
    Inventors: David Chapman, Martin Lindsjö, Hans Lönn, Michael Lundkvist, Magnus Munck AF Rosenschöld, Antonios Nikitidis, Debra Ainge, John Pavey
  • Metalloproteinase inhibitors
    Patent number: 8153673
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: April 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Metalloproteinase Inhibitors
    Publication number: 20110003853
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Application
    Filed: July 6, 2010
    Publication date: January 6, 2011
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenchöld, Pavol Zlatoidsky
  • MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS
    Publication number: 20110003858
    Abstract: The invention provides compounds of formula (I) and formula (IV) (M)-(L)-(M) (I) [(M)-(L4)]t-G (VI) wherein M, L, L4, G and t are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: September 3, 2007
    Publication date: January 6, 2011
    Inventors: Lena Bergström, Hans Lönn, Michael Lundkvist, Peter Sjö
  • Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
    Publication number: 20100280048
    Abstract: The invention provides certain novel 6-heteroaryl-5-methyl-3-oxo-4-[3(trifluoromethyl)phenyl]-3,4-dihydropyrazine-2-carboxamide derivatives and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: November 5, 2008
    Publication date: November 4, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Debra Ainge, David Chapman, Martin Lindsjo, Hans Lonn, Michael Lundkvist, Magnus Munck AF Rosen-Schold, Antonios Nikitidis, John Pavey
  • Metalloproteinase Inhibitors
    Publication number: 20100273849
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Application
    Filed: January 26, 2010
    Publication date: October 28, 2010
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenchöld, Pavol Zlatoidsky
  • Novel Hydantoin Derivatives as Metalloproteinase Inhibitors
    Publication number: 20100256166
    Abstract: The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.
    Type: Application
    Filed: February 1, 2010
    Publication date: October 7, 2010
    Inventors: Balint Gabos, Michael Lundkvist, Magnus Munck Af Rosenschold, Igor Shamovsky, Pavol Zlatoidsky
  • Metalloproteinase inhibitors
    Patent number: 7754750
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: July 13, 2010
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Hydantoin derivatives as metalloproteinase inhibitors
    Patent number: 7700604
    Abstract: The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: April 20, 2010
    Assignee: AstraZeneca AB
    Inventors: Balint Gabos, Michael Lundkvist, Magnus Munck Af Rosenschold, Igor Shamovsky, Pavol Zlatoidsky
  • Metalloproteinase inhibitors
    Patent number: 7666892
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: February 23, 2010
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Hydantoin derivatives as metalloproteinase inhibitors
    Patent number: 7655664
    Abstract: The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: February 2, 2010
    Assignee: AstraZeneca AB
    Inventors: Balint Gabos, Michael Lundkvist, Magnus Munck Af Rosenschold, Igor Shamovsky, Pavol Zlatoidsky
  • Metalloproteinase inhibitors
    Patent number: 7625934
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: December 1, 2009
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Metalloproteinase Inhibitors
    Publication number: 20080306065
    Abstract: Compounds of the formula (I) wherein z is SO2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Application
    Filed: May 6, 2008
    Publication date: December 11, 2008
    Inventors: Anders Eriksson, Matti Lepisto, Michael Lundkvist, Magnus Munck Af Rosenschold, Pavol Zlatoidsky